Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC-1291 in Cancer Anorexia/Cachexia
NCT00267358Phase 2
Key facts
- Status
- Completed
- Start
- Nov 2005
- Primary completion
- Oct 2006
- Countries
- 1
- Modality
- Small Molecules
- Drugs
- anamorelin
- Conditions
- cancer cachexiaanorexia nervosa (AN)
01
Overview
Phase 2, randomised, double-blind trial in cancer cachexia and anorexia nervosa (AN) comparing RC-1291 HCl with Placebo (2 arms). Primary endpoints: Body weight at 12 weeks, Lean body mass at 12 weeks and 1 more. Started Nov 2005; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
RC-1291 HCl
RC-1291 HCl 50 mg
Placebo
Placebo
03
Who it enrols
Community-dwelling patients >= 18 years with incurable cancer and involuntary weight loss >= 5% in the past 6 months.
04
Endpoints
Primary
Body weight
Lean body mass
Functional performance
Beyond the preview
Go deeper on NCT00267358.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00267358.